Article Sidebar

PDF
Date Published: 13/09/2021
Abstract Views: 2419
Views PDF: 460
DOI: https://doi.org/10.51298/vmj.v505i2.1105
Issue
Vol. 505 No. 2 (2021)
Section
Các bài báo
How to Cite
Duy Mạnh, P. ., & Lê Huy, T. . (2021). RESULTS OF R-CHOP THERAPY IN DIFFUSE LARGE B-CELL NON-HODGKIN LYMPHOMA. Vietnam Medical Journal, 505(2). https://doi.org/10.51298/vmj.v505i2.1105

RESULTS OF R-CHOP THERAPY IN DIFFUSE LARGE B-CELL NON-HODGKIN LYMPHOMA

Phạm Duy Mạnh1, Trịnh Lê Huy1,2,
1 Hanoi Medical University
2 Hanoi Medical University Hospital

Main Article Content

Abstract

Objectives: To evaluate the treatment results of R-CHOP therapy in diffuse large B-cell non-hodgkin lymphoma. Patients and Methods: Descriptive, retrospective study on 35 patients treated with R-CHOP therapy at Hanoi Medical University Hospital from January 2015 to June 2021. Results: Clinicopathologic characteristics: Mean age was 57±13.7, male: female = 1.2:1. Nearly all patients had good performance status (94.3%). Peripheral lymph nodes detected was the most common presenting symptom (40%). A third of all patients had extralymph node disease (34.3%). 65.7% of all participants had elevated LDH enzyme before treatment. Treatment results and adverse events: complete response rate after 3 cycles was 28.6%, after 6 cycles was 82.9%. At the median follow up of 3 years, progression free survival rate was 87.8%. Neutropenia was the most common adverse events, in which only 5.8% had grade 3 or 4 toxicity. Conclusion: R-CHOP therapy was safe and highly effective in diffuse large B-cell lymphoma patients.

Article Details

Keywords

R-CHOP, Diffuse large B cell non Hodgkin lymphoma

References

1. Sung, H., Ferlay, J., Siegel, R. L., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3), 209-249.
2. Shi, Y., Han, Y., Yang, J., et al. (2019). Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China. Chinese journal of cancer research, 31(1), 152–161.
3. Rovira, J., Valera, A., Colomo, L., Setoain, X., Rodríguez, S., Martínez-Trillos, A., Giné, E., Dlouhy, I., Magnano, L., Gaya, A., Martínez, D., Martínez, A., Campo, E., & López-Guillermo, A. (2015). Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Annals of hematology, 94(5), 803–812.
4. Pfreundschuh, M., Trümper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P. L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., López-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., … MabThera International Trial Group (2006). CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The Lancet. Oncology, 7(5), 379–391. https://doi.org/10.1016/S1470-2045(06)70664-7
5. Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., Belhadj, K., Bordessoule, D., Fermé, C., & Tilly, H. (2010). Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, 116(12), 2040–2045. https://doi.org/10.1182/blood-2010-03-276246
6. Trần Xuân Dũng, (2018). Đánh giá kết quả điều trị bệnh u lympho ác tính không Hodgkin tế bào B lớn lan tỏa tái phát, Luận văn thạc sĩ y học, Đại học Y Hà Nội.
7. Phạm Thị Quế. (2012). Đánh giá kết quả điều trị hóa chất phác đồ r-chop trong u lympho ác tính không hodgkin tế bào B tại bệnh viện K, Luận văn thạc sĩ y học, Đại học Y Hà Nội.